[HTML][HTML] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

…, M Jevnikar, D Montani, S Bulifon… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study

…, C Dauphin, F Picard, S Bulifon… - European …, 2014 - Eur Respiratory Soc
Patients with severe pulmonary arterial hypertension (PAH) in New York Heart Association (NYHA)
functional class (FC) III/IV have a poor prognosis, despite survival benefits being …

Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension

…, A Bourdin, H Bouvaist, S Bulifon… - American journal of …, 2021 - atsjournals.org
Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

…, MF Bellin, N Noël, S Bulifon… - European …, 2020 - Eur Respiratory Soc
Background Viral respiratory infections are the main causes of asthma exacerbation. The
susceptibility of patients with asthma to develop an exacerbation when they present with …

Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission

…, M Preda, A Beurnier, S Bulifon… - European …, 2021 - Eur Respiratory Soc
A high prevalence of venous thromboembolism (VTE) has been reported during intensive
care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID-19) [1…

Pulmonary arterial hypertension in patients treated with interferon

…, X Jaïs, A Seferian, R Jovan, S Bulifon… - European …, 2014 - Eur Respiratory Soc
Isolated cases of pulmonary arterial hypertension (PAH) in patients treated with interferon (IFN)
α or β have been reported in the literature. The aim of this study was to describe all …

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

…, M Jevnikar, D Montani, S Bulifon… - The Lancet …, 2022 - thelancet.com
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a …

[HTML][HTML] Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …

…, R Gaci, M Andreu, E De Magalhaes, S Bulifon… - …, 2023 - thelancet.com
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …

COVID-19 in patients with pulmonary hypertension: a national prospective cohort study

…, J Weatherald, X Jaïs, S Bulifon… - American Journal of …, 2022 - atsjournals.org
Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
associated with pulmonary endothelial dysfunction. There are limited data available on the …

[HTML][HTML] Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome

…, X Jaïs, T Pham, L Morin, A Boucly, S Bulifon… - ERJ open …, 2022 - Eur Respiratory Soc
Rationale The characteristics of patients with respiratory complaints and/or lung radiologic
abnormalities after hospitalisation for coronavirus disease 2019 (COVID-19) are unknown. …